MDM2 and cancer: Furthermore, results from the in silico GI screens identified several SL candidates—namely NDUFB5 (in the STAD screen), MDM2 and TUBA1B (in the COAD/READ screen), and WRN (in the pan-cancer and COAD/READ screens)—which encode proteins that can be inhibited using existing and in-development drugs.